文献速递角膜与眼表疾病

角膜内皮疾病治疗的演变:过去、现在与未来的方法

Evolution of therapies for the corneal endothelium: past, present and future approaches.
PubMed 文献 · Br J Ophthalmol · 2020-07-24

本文综述角膜内皮疾病的移植治疗演变:内皮角膜移植术(EK)较传统穿透性角膜移植术视觉恢复更快、免疫排斥率更低、移植物存活更优,但全球供体角膜短缺、技术门槛与成本限制其应用;再生医学与细胞疗法是减少对异体组织依赖的潜在新方向。

要点

  • 内皮角膜移植术(DSAEK、DMEK)较穿透性角膜移植术视觉恢复更快且排斥率更低。
  • 供体角膜短缺、专业技术要求高、费用高与移植物排斥或失败限制传统移植。
  • 再生医学与细胞疗法是减少对异体组织依赖的潜在替代治疗方向。

核心结论

  • 内皮角膜移植术已成为角膜内皮疾病移植治疗的重要演变方向,但传统移植仍受供体短缺、技术、费用与排斥风险限制。
  • 再生医学与细胞疗法是可能转化为临床实践的潜在新疗法,旨在减少对异体角膜组织的依赖。

研究设计与样本

  • 本文为综述,概述过去与现在的角膜内皮疾病移植手术,并介绍可能转化为临床实践的新型疗法。

主要发现

  • 近15年引入的内皮角膜移植术(EK)选择性替换病变角膜内皮,显著改变了角膜移植领域。
  • 与传统穿透性角膜移植术相比,DSAEK与DMEK视觉恢复更快、免疫排斥率更低、移植物存活改善。

临床怎么用

  • 角膜内皮疾病是角膜移植的主要适应证之一,临床可依据病情选择内皮角膜移植术式。
  • 需权衡供体可获得性、专业技术与成本,并关注排斥与失败风险。
  • 再生医学与细胞疗法目前仍属研究阶段,尚不作为常规临床推荐。

局限性

  • 本文为综述,未提供原始研究的具体样本量、效应量或统计学阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Corneal endothelial diseases are leading indications for corneal transplantations. With significant advancement in medical science and surgical techniques, corneal transplant surgeries are now increasingly effective at restoring vision in patients with corneal diseases. In the last 15 years, the introduction of endothelial keratoplasty (EK) procedures, where diseased corneal endothelium (CE) are selectively replaced, has significantly transformed the field of corneal transplantation. Compared to traditional penetrating keratoplasty, EK procedures, namely Descemet's stripping automated endothelial keratoplasty (DSAEK) and Descemet membrane endothelial keratoplasty (DMEK), offer faster visual recovery, lower immunological rejection rates, and improved graft survival. Although these modern techniques can achieve high success, there are fundamental impediments to conventional transplantations. A lack of suitable donor corneas worldwide restricts the number of transplants that can be performed. Other barriers include the need for specialized expertise, high cost, and risks of graft rejection or failure. Research is underway to develop alternative treatments for corneal endothelial diseases, which are less dependent on the availability of allogeneic tissues - regenerative medicine and cell-based therapies. In this review, an overview of past and present transplantation procedures used to treat corneal endothelial diseases are described. Potential novel therapies that may be translated into clinical practice will also be presented.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Ong HS, Ang M, Mehta JS, et al. Evolution of therapies for the corneal endothelium: past, present and future approaches. Br J Ophthalmol. 2020. PMID: 32709756. doi:10.1136/bjophthalmol-2020-316149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。